1. Determina G.U. 74 del 21/03/2020. Ordinanza n. 651 del 19/03/2020.
2. Determina 662/2013, G.U. n.175 del 27/07/2013
3. Determina G.U. 41/42 del 24/02/2007
4. Determina G.U. 195 del 21/08/2013
5. Determina G.U. 278 del 28/11/2017
6. Cosmi B. Management of superficial vein thrombosis. J Thromb Haemost 2015; 13: 1175–83
7. Scott G, Mahdi AJ, Alikhan R. Superficial vein thrombosis: a current approach to management. British Journal of Haematology, 2015; 168: 639–64
8. Delavenne X, Frappe´P, Zufferey P et al. PK evaluation of fondaparinux sodium for the treatment of thrombosis. Expert Opin Drug Metab Toxicol 2014; 10 (2)
9. RCP ARIXTRA 2,5 mg 
10. Decousus H, Prandoni P, Mismetti P et al. for the CALISTO Study Group. Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs. N Engl J Med 2010; 363:1222-32
11. Beyer-Westendorf J, et al Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol. 2017; 4(3):e105-e113
12. Blin P, Sevestre MA, Pouchain D, Gillet JL.Management and 3-month outcomes of isolated superficial vein thrombosis of the lower limb: A real-world cohort study. Thrombosis Research 2017; 157:117-119
13. Duffett L et al. Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-Analysis. Thromb Haemost 2019;119(3):479-489
14. RCP ARIXTRA 5 mg
15. RCP ARIXTRA 7,5 mg
16. RCP ARIXTRA 10 mg
17. RCP ARIXTRA 1,5 mg